empower pharmacy retatrutide Compounded Medications for Peptides Empower Pharmacy for Providers |

A 52-week phase 2 trial on AMG133 in people with overweight and obesity is ongoing (NCT05669599)

Independent Wellness offers personalized plans with refill coordination and lifestyle support, serving patients in approved states with licensed prescribers

Retatrutide is a novel triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, placing it in a distinct class from existing weight-management treatments such as semaglutide and tirzepatide

Chiu WY, Shih SR, Tseng CH

21 August 2020 [Initial approval 4 January 2018]

Research peptide suppliers represent the primary source for those seeking Retatrutide before regulatory approval